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Hyperinsulinism (HI) is the leading cause of persistent hypoglycemia in children, which if unrecognized may lead to
development delays and permanent neurologic damage. Prompt recognition and appropriate treatment of HI are
essential to avoid these sequelae. Major advances have been made over the past two decades in understanding
the molecular basis of hyperinsulinism and mutations in nine genes are currently known to cause HI. Inactivating
KATP channel mutations cause the most common and severe type of HI, which occurs in both a focal and a diffuse
form. Activating mutations of glutamate dehydrogenase (GDH) lead to hyperinsulinism/hyperammonemia
syndrome, while activating mutations of glucokinase (GK), the “glucose sensor” of the beta cell, causes
hyperinsulinism with a variable clinical phenotype. More recently identified genetic causes include mutations in the
genes encoding short-chain 3-hydroxyacyl-CoA (SCHAD), uncoupling protein 2 (UCP2), hepatocyte nuclear factor
4-alpha (HNF-4α), hepatocyte nuclear factor 1-alpha (HNF-1α), and monocarboyxlate transporter 1 (MCT-1), which
results in a very rare form of HI triggered by exercise. For a timely diagnosis, a critical sample and a glucagon
stimulation test should be done when plasma glucose is < 50 mg/dL. A failure to respond to a trial of diazoxide, a
KATP channel agonist, suggests a KATP defect, which frequently requires pancreatectomy. Surgery is palliative for
children with diffuse KATPHI, but children with focal KATPHI are cured with a limited pancreatectomy. Therefore,
distinguishing between diffuse and focal disease and localizing the focal lesion in the pancreas are crucial aspects
of HI management. Since 2003, 18 F-DOPA PET scans have been used to differentiate diffuse and focal disease and
localize focal lesions with higher sensitivity and specificity than more invasive interventional radiology techniques.
Hyperinsulinism remains a challenging disorder, but recent advances in the understanding of its genetic basis and
breakthroughs in management should lead to improved outcomes for these children.
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Congenital hyperinsulinism (HI) is the most common
cause of persistent hypoglycemia in infants and children,
which if unrecognized may lead to development delays
and permanent neurologic damage. In general, the high
risk of brain damage appears to be due to delays in diag-
nosis and treatment rather than a consequence of the
genetic defects and, thus, is potentially preventable [1].* Correspondence: deleon@chop.edu
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distribution, and reproduction in any mediumWithin the last two decades, major advances have
been made in understanding the molecular and genetic
basis of HI. This work has helped elucidate the physi-
ology of beta cell function and insulin regulation, as well
as advanced clinical care for children with HI. Among
the nine known genetic causes of HI, mutations in the
genes encoding the ATP-sensitive potassium channel
represent the most common defect accounting for the
majority of the cases [2]. At least 50% of the children
carrying these mutations have a focal form of the disease
and can be cured by surgery, thanks to the introduction
of novel imaging techniques. In this article, we will review
the genetic basis of HI with a focus on the recently identi-
fied genetic causes and mechanisms of disease, describeentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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advances in the management of this challenging disorder.Molecular genetics
Nine genes expressed in the ß-cell have been implicated
in the pathophysiology of HI [Figure 1]. They include
ABCC8 and KCNJ11 encoding SUR-1 and Kir6.2, the
two subunits of the ATP-sensitive potassium channel
(KATP channel); GLUD1 encoding glutamate dehydrogen-
ase (GDH); GCK encoding glucokinase (GK); HADH en-
coding short-chain 3-hydroxyacyl-CoA (SCHAD); UCP2
encoding uncoupling protein 2 (UCP2); HNF4A and
HNF1A encoding the transcription factors hepato-
cyte nuclear factor 4-alpha (HNF-4α) and hepatocyte
nuclear factor 1-alpha (HNF-1α), respectively; and
ectopic expression of monocarboxylate transporter 1
(MCT-1) encoded by SLC16A1. Many of these genes
are also involved in the pathogenesis of monogenic dia-
betes, including ABCC8, KCNJ11, GCK, HNF4A, and
HNF1A. There remain approximately 50% of diazoxide-
responsive cases and 10% of diazoxide-unresponsive
cases of HI with unknown genetic etiology, suggesting
that additional, yet to be identified genes are implicated














Figure 1 Genetic defects in the beta cell leading to hyperinsulinism. I
to inhibition and closure of ATP-sensitive potassium channels, which trigge
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ADP = adenosine diphosphate.KATP-hyperinsulinism
Inactivating mutations in the genes encoding the two sub-
units of the ß-cell ATP-sensitive potassium channel (KATP
channel), ABCC8 and KCNJ11 (encoding SUR-1 and
Kir6.2, respectively), cause the most common and severe
form of hyperinsulinism, although mutations in ABCC8
are more common [4,5]. The effect of these mutations
on channel expression and function determines the clin-
ical phenotype, particularly the response to diazoxide,
a KATP channel opener used in the treatment of HI [2].
Thus, KATPHI can been classified into three sub-
types: (1) recessive diazoxide-unresponsive, (2) dominant
diazoxide-unresponsive and (3) dominant diazoxide-
responsive [6-9]. Clinically, the first two groups are
undistinguishable. These children present as neonates
with large for gestational age birth weights and severe
hypoglycemia that requires high glucose infusion rates
and fails to respond to therapy with diazoxide, because
there are no functional KATP channels (recessive defects)
or their function is severely impaired (dominant defects)
[8]. Therefore, children with recessive or dominant
diazoxide-unresponsive KATPHI, frequently require
pancreatectomy to control their hypoglycemia. The third
group (dominant diazoxide-responsive) typically has less















n the pancreatic beta cell, ATP production from fuel metabolism leads
rs membrane depolarization and opening of voltage-dependent
secretion. Defects in this pathway can result in hyperinsulinism. The
tations: SUR-1 (sulfonylurea receptor), Kir6.2 (potassium channel),
tein 2), HNF-4α (hepatic nuclear transcription factor 4α), and HNF-1α
and are not depicted in the figure. Three are activating mutations: GK
ransporter 1). Positive effects are shown by a plus arrow; negative
ay. G6P = glucose-6-phosphate, ATP = adenosine triphosphate,
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failure to suppress insulin secretion as glucose concen-
tration falls, manifesting as severe fasting hypoglycemia,
and a failure to increase insulin secretion in response to
a glucose load [2]. In contrast to the impaired glucose-
stimulated insulin secretion, amino acids trigger insulin
release in some individuals with KATPHI, causing severe
protein-induced hypoglycemia [10].
In the 1980s, it was recognized that some patients with
severe hyperinsulinism were cured after a partial pancrea-
tectomy. On histologic inspection, although the majority
of their pancreas appeared normal, a focal “tumor-like”
area of abnormal beta cell proliferation was identified. In
contrast, children who were not cured with surgery had a
normal number of beta cells, but these cells showed signs
of hyperactivity throughout the pancreas [11]. These find-
ings lead to the recognition of two distinct histologic
forms of HI: diffuse and focal. The molecular mechanism
responsible for these focal adenomatous lesions in which
abnormal beta cell proliferation occurs in a discrete region
of the pancreas was later described [12]. The pathophysi-
ology of focal KATPHI includes a “two hits” mechanism:
first, a paternally inherited recessive mutation in ABCC8
or KCNJ11; and second, a deletion of the maternally inher-
ited 11p15 chromosomal region, compensated by paternal
uniparental disomy [13]. The loss of maternally expressed
genes involved in tumor suppression explains the histo-
logical findings of focal KATPHI [12,14].
Clinically, children with the focal form are indistin-
guishable from those with the recessive diffuse form,
presenting with severe hypoglycemia and high glucose
requirements. Unlike the diffuse form, focal KATPHI may
be cured with surgical resection of the discrete lesion.
Thus, the recognition of these cases prior to surgery is
critical as explained later.
Recently, a novel “atypical” form of focal hyperinsulin-
ism consisting of morphologic mosaicism of pancreatic
islets has been reported, which similar to focal lesions,
involves only a portion of the pancreas and may be cured
with partial pancreatectomy [15]. The histology in this
form shows co-existence of two abnormal islet types (large
islets with occasional enlarged nuclei and shrunken islets
with small nuclei) in a limited region of the pancreas. No
mutations in ABCC8, KCNJ11 or GCK were identified in
these cases and the molecular mechanism is unknown at
this time.
GDH-hyperinsulinism
The second most common form of HI is due to activating
mutations of glutamate dehydrogenase (GDH), encoded
by GLUD1, leading to the hyperinsulinism/hyperammone-
mia (HI/HA) syndrome [16]. In the beta cell, GDH is
involved in amino acid-stimulated insulin secretion and
loss of inhibitory control of GDH in HI/HA leads todysregulated insulin secretion. The majority of mutations
in GLUD1 occur de novo (70%) with the reminder
inherited in an autosomal dominant pattern [17]. Indivi-
duals with HI/HA have fasting and protein-induced
hypoglycemia, which is easily controlled with diazoxide.
Ammonia levels are typically elevated 3–5 times the normal
range, but these individuals do not exhibit the classical
symptoms associated with hyperammonia due to other
causes. Children with HI/HA have increased rates of
seizures, most commonly atypical absence, and learning
disabilities [18]. These neurologic abnormalities appear to
be unrelated to hypoglycemia or elevated ammonia levels.
GK-hyperinsulinism
Activating mutations in glucokinase (GK) cause an auto-
somal dominant form of HI. Glucokinase, encoded by
GCK, is the “glucose sensor” of the beta cell, triggering in-
sulin secretion in response to rising glucose concentration
[19]. Activating mutations lower the threshold for insulin
release; thus, the glucose set point for these individuals is
lower. GK-HI presents with fasting hypoglycemia of vari-
able degrees of severity and, although the initial reported
case responded well to diazoxide, less than a third of
the reported cases have been treated successfully with
diazoxide [2,20].
SCHAD-hyperinsulinism
Short-chain 3-hydroxyacyl-CoA (SCHAD) deficiency
leads to an autosomal recessive form of HI. SCHAD,
encoded by HADH, catalyzes a step in the fatty acid oxi-
dation (FAO) cycle [21]. Although FAO defects are well
known to cause hypoglycemia, the connection between
an enzyme in the FAO cycle and HI was unclear. Subse-
quently, it was shown that SCHAD is an inhibitory
regulator of GDH, the enzyme involved in amino-acid
stimulated insulin secretion, and loss of GDH’s inhib-
ition due to SCHAD deficiency results in insulin dysre-
gulation [22]. Children with SCHAD-HI have fasting
and protein-induced hypoglycemia and similar to
patients with HI/HA, they respond well to diazoxide
therapy. Biochemical markers of SCHAD-HI include
increased concentration of 3-hydroxybutyrylcarnitine in
plasma and 3-hydroxyglutaric acid in urine. These chil-
dren do not exhibit the cardiac, skeletal or hepatic dys-
function associated with FAO disorders.
UCP2-Hyperinsulinism
Uncoupling protein 2 (UCP2), a membranous mitochon-
drial carrier, acts as a negative regulator of insulin secretion
in the beta cells. Recently, loss of function mutations in
UCP2 have been described that result in hyperinsulinism
[23]. UCP2 mutations are inherited in an autosomal domin-
ant manner and have been identified in children responding
to diazoxide. The reported cases have resolution of HI by
Lord and De León International Journal of Pediatric Endocrinology 2013, 2013:3 Page 4 of 9
http://www.ijpeonline.com/content/2013/1/37 months to 6 years of age, which suggests that UCP2-HI is
a transient disorder [2].HNF4A and HNF1A-hyperinsulinism
Hepatocyte nuclear factor 4-alpha (HNF-4α), a tran-
scription factor involved in pancreatic development and
function, has been classically linked to a monogenic
form of early-onset diabetes, MODY1 [24]. Mutations in
HNF4A, which encodes HNF-4α, have an autosomal
dominant pattern of inheritance. A study of families with
MODY1 found that carriers of HNF4A mutations were
born macrosomic and 8 carriers had transient neonatal
hypoglycemia with hyperinsulinism identified in 3 of the
8 [25]. Further studies demonstrated HNF4A mutations
in children presenting with diazoxide-responsive HI
[26]. Patients with HNF4A mutations respond well to
diazoxide and the HI resolves within the first year of life
in the majority of cases, although cases of persistent HI
caused by HNF4A mutations have been reported [27].
The phenotype in these cases is complex and may in-
volve the liver and kidney [28]. Recently, mutations
in the transcription factor, hepatocyte nuclear factor
1-alpha (HNF-1α), encoded by HNF1A and known to
cause MODY3, have been shown to also present with
hyperinsulinism in infancy [28]. The mechanism by
which loss of function mutations in HNF4A and HNF1A
can lead to this dual phenotype with hypoglycemia in
early life and diabetes later, has not been elucidated, but
likely implies a changing pattern of gene expression
regulation by these transcription factors throughout the
life of an individual.MCT1-Hyperinsulinism
Aberrant expression of monocarboxylate transporter 1
(MCT-1) leads to a very rare and unusual form of hyper-
insulinism, which is triggered by exercise. Identified in
two Finnish families, exercise-induced hyperinsulinism
(EIHI) is characterized by episodes of hypoglycemia
associated with elevated insulin levels at the time of an-
aerobic exercise [29]. Autosomal dominant mutations in
the regulatory regions of the SLC16A1 gene, which
encodes MCT-1, have been identified [30]. In normal
individuals, MCT-1, a transporter of pyruvate and lac-
tate, is not expressed on beta cells, but in EIHI, muta-
tions in the regulatory regions of SLC16A1 lead to
expression of MCT-1 on beta cells. The presence of
MCT-1 allows pyruvate, elevated during anaerobic exer-
cise, to enter the beta cell and through the triggering
pathway (KATP-mediated), increase insulin release result-
ing in hypoglycemia [31]. The degree of hypoglycemia
associated with exercise is variable and is only partially
responsive to diazoxide.Diagnosis
For children presenting with hypoglycemia (plasma glu-
cose < 70 mg/dL), prompt diagnosis and establishment
of effective treatment is essential to avoid neurologic se-
quelae. Clinical clues to the diagnosis of the HI include
large for gestational age birth weight and severe, persist-
ent hypoglycemia requiring high glucose infusion rates
(> 10 mg/kg/min). However, the clinical phenotype of
hyperinsulinism is a spectrum and infants with HI can
also present with normal birth weights and lower glu-
cose requirements.
The diagnosis of hyperinsulinism is made based on the
critical sample obtained during a spontaneous or pro-
voked hypoglycemic event. The threshold blood glucose
to obtain the critical sample by convention is set low at <
50 mg/dL to decrease the likelihood of false positive
results. If a diagnostic fast is needed to obtain the critical
sample, close monitoring of blood glucose, vital signs and
mental status is essential to ensure the patient’s safety. Par-
ental dextrose, as well as all appropriate specimen collec-
tion tubes, should be at the bedside prior to the start of
the fast. Upon completion of diagnostic testing, blood glu-
coses should be monitored every 10–15 min until they are
reliably above 70 mg/dL.
In addition to obtaining the critical sample, the glycemic
response to glucagon should be evaluated [Table 1]. A de-
tectable insulin level is inappropriate at the time of
hypoglycemia and is consistent with insulin excess. A
common pitfall in the diagnosis of HI is that insulin con-
centration is not always elevated, even at the time of
hypoglycemia, thus the diagnosis should be based on other
indicators of increased insulin action [32]. Laboratories
consistent with excess insulin action include suppressed
beta-hydroxybutyrate and free fatty acid concentrations as
well as an inappropriate glycemic response to glucagon of
30 mg/dL or more at the time of hypoglycemia [33].
In cases with overgrowth and failure to respond to diaz-
oxide and octreotide, activating mutations in AKT2
should be considered in the differential diagnosis [34].
Beckwith-Wiedemann syndrome, neonatal panhypopitui-
tarism and congenital disorders of glycosylation should
also be considered and appropriately evaluated if war-
ranted by clinical features. Beckwith-Wiedemann syn-
drome has significant clinical heterogeneity and is
characterized by hemihypertrophy, macrosomia, macro-
glossia and predisposition to embryonal tumors. Neonates
with panhypopituitarism may have diagnostic findings
identical to HI with suppressed ketones and free fatty
acids and a glycemic response to glucagon. Clinical fea-
tures suggestive of panhypopituitarism include midline
defects and micropenis. Congenital disorders of glycosyla-
tion are a highly variable group of disorders caused by ab-
normal glycosylation of N-linked oligosaccharides and
hypoglycemia may be found with failure to thrive and liver
Table 1 Criteria for diagnosing hyperinsulinism
Clinical Clues Large for gestational age
GIR > 10 mg/kg/min#
Lab findings with
glucose < 50 mg/dL
↓ Beta-hydroxybutyrate (< 0.6 mM)
↓ Free fatty acids (< 0.5 mM)
+/− ↑ Insulin
Glycemic Response to Glucagon* ↑ Glucose > 30 mg/dL
* Glucagon stimulation test: When glucose < 50 mg/dL, administer 1 mg
glucagon IV/IM and monitor glucose every 10 min for 40 min. If there is no
increase in blood glucose by 20 min, terminate test and rescue with IV
dextrose. GIR = glucose infusion rate.
# Please note that in some cases the GIR may be lower.
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of hypoglycemia are not diagnostic of growth hormone
deficiency or adrenal insufficiency and the appropriate
stimulation tests should be performed to confirm those
diagnoses [35]. Insulinomas should be considered in the
differential diagnosis of children presenting with hyperin-
sulinemic hypoglycemia beyond infancy, particularly dur-
ing the second decade of life.
A failure to respond to maximum dose of diazoxide
(15 mg/kg/day) after at least 5 days of treatment, suggests
a KATP channel defect as the most likely cause of hyperin-
sulinism. Such children are potential surgical candidates
and require referral to a specialized HI center with 18-
fluoro L-3,4-dihydroxyphenylalanine positron emission
tomography (18 F-DOPA PET) scan availability [Figure 2].Diagnosis of HI 5 day trial of D
Safety Fas


















Figure 2 Algorithm for the treatment of hyperinsulinism. Assessing th
Patients who fail to respond to diazoxide will most likely have KATP channe
scan capability. A safety fast should be 8 to 18 h long depending on the a
operative treatment in neonates with HI due to high rate of treatment failu
channel, 18 F DOPA PET = 18-fluoro L-3,4-dihydroxyphenylalanine positronCommercial genetic testing is available for the four most
common HI genes (ABCC8, KCNJ11, GLUD1 and GCK)
and for the HNFs defects. As a cost-reducing measure,
genetic testing should be targeted based on the clinical
phenotype; for example sending for GLUD1 in children
who are responsive to diazoxide and have elevated ammo-
nias. Our recommendation is to send genetic testing as
soon as possible for the child and his/her parents, espe-
cially for the diazoxide-unresponsive cases as the detection
of a single recessive paternal KATP mutation (ABCC8 or
KCNJ11) has a positive predictive value of 94% for focal
hyperinsulinism [3].
Management
The therapeutic goal for hyperinsulinism as well as other
hypoglycemic disorders is to achieve and maintain plasma
glucoses greater than 70 mg/dL. In the 1960s, the antihy-
pertensive, diazoxide with its known side effect of hyper-
glycemia, was first used to treat hyperinsulinism [36]. The
1970s saw the introduction of octreotide as an HI treat-
ment [37]. These drugs remain the mainstay of medical
treatment for HI. Diazoxide acts to open the KATP chan-
nel, decreasing insulin secretion and is the first-line agent
for HI, although most cases of KATPHI do not respond.
The therapeutic dose range of diazoxide is wide (5 to
15 mg/kg/day) and varies according to the severity of
the phenotype. Patients with severe hypoglycemia and
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with more mild disease can be started on doses of 5–
10 mg/kg/day, which should be increased if there is no
response after several days of treatment. The half-life of
diazoxide in children is between 9.5-24 h [38] and is un-
known in neonates, leading to controversy as to whether
twice a day or three times a day dosing is appropriate. In
general, we find that for diazoxide-responsive children,
dosing twice daily is sufficient to provide appropriate
control. To evaluate diazoxide’s efficacy after 5 days of
therapy, a safety fast should be performed with a dur-
ation lasting 8 to 18 h based on the age of the patient.
Continued hypoglycemia after at least 5 days of the max-
imum dose (15 mg/kg/day) is considered a treatment
failure. The side effects of diazoxide include hypertrichosis
and fluid retention. Hypertrichosis is often quite severe,
but resolves after stopping the drug. Fluid retention, espe-
cially in neonates, may require the use of a diuretic, such
as chlorothiazide, but stronger loop diuretics should be
avoided.
The second-line agent, octreotide decreases insulin se-
cretion through hyperpolarization of the beta cells and in-
hibition of calcium channels. Octreotide is associated with
frequent treatment failure due to the development of
tachyphylaxis. More importantly, octreotide has recently
been associated with the occurrence of fatal necrotizing
enterocolitis and therefore, should be used with caution in
neonates [39]. Our center no longer recommends its use
in neonates pre-operatively. It continues to be used post-
operatively in children with diffuse disease who remain
hypoglycemic following subtotal pancreatectomy. Success-
ful treatment with long-acting formulations of octreotide
has recently been reported [40,41].
Glucagon can be used as a continuous intravenous
infusion of 1 mg/day to lower glucose infusion rate
requirements in infants awaiting surgery. Trials of glu-
cagon as a subcutaneous infusion through a pump were
largely unsuccessful due to the drug’s lack of stability in
solution [42,43]. A new potential therapeutic approach
to children with KATP defects involves inhibition of
GLP-1 action, an incretin known to increase insulin
secretion and lower blood glucose. Recently, a GLP-1
receptor antagonist, exendin-(9–39) has been shown to
elevate fasting blood glucose in individuals with hyper-
insulinism [44].
Surgical intervention is indicated in children who have
a focal lesion that can be cured with resection and in
children with diffuse disease who fail medical therapy.
Pursuing surgery in the latter group requires a careful
consideration of risks and benefits. The benefit of sur-
gery in this group is that their hypoglycemia is often eas-
ier to manage following a pancreatectomy, but this must
be weighed against the risks of a surgical procedure
and long-term complications, such as diabetes. Thosechildren with diffuse disease who have very limited fast-
ing tolerances (less than 2–3 h) and very high glucose
infusion requirements will most likely require a pancrea-
tectomy. However, some children with diffuse disease
and longer fasting tolerances (6–8 h) may be managed
with a combination of frequent feeds, enteral dextrose
and/or octreotide. The risks of this management ap-
proach include potentially more frequent hypoglycemia
and exposure to octreotide.
The largest advance in the management of children
with HI over the past decade was the introduction of
imaging with 18 F-DOPA PET to differentiate focal from
diffuse disease and to localize focal lesions [45]. As dis-
cussed earlier, children with focal KATPHI can be cured
with surgical resection of the lesion. In contrast, for chil-
dren with diffuse HI, surgery is palliative. Differentiating
focal from diffuse disease and accurately identifying the
location of focal lesions in the pancreas is crucial for en-
suring that children with focal KATPHI are successfully
cured. Conventional imaging techniques, such as CT or
MRI, cannot identify focal lesions and interventional
radiology techniques, such as transhepatic portal venous
sampling or arterial calcium stimulation are highly inva-
sive and have poor accuracy for differentiating diffuse
from focal HI and for localizing the focal lesion [46].
The uptake of 18 F-DOPA identifies neuroendocrine
tissue, which takes up amino acid precursors of dopa-
mine, including DOPA. In diffuse HI, the uptake of the
tracer is uniform throughout the pancreas; in contrast, a
focal lesion will have greater uptake in a specific region
compared to the surrounding tissue [Figure 3]. Since
2003, 18 F-DOPA PET scans have been used to differenti-
ate diffuse from focal HI and to localize focal lesions
prior to surgery [47]. In the largest series to date of 50
patients who underwent 18 F-DOPA PET scans, followed
by surgery, the sensitivity for diagnosing focal disease
was 75% and the location of the focal was correctly iden-
tified in 100% of cases [45]. Similar results have been
reported in smaller series [48,49]. A meta-analysis in
2012 showed superiority of the 18 F-DOPA PET scan
compared to interventional radiology techniques for
diagnosing and localizing focal lesions [50].
Accurate localization of the focal lesion aids in pre-
operative planning and in select cases (lesions on the an-
terior surface of the body and tail), allows for the use of
laparoscopic techniques [2]. Intraoperative biopsies and
frozen section evaluation by experienced pathologists
allows for confirmation of a focal lesion and guides the
extent of pancreatic resection. Children with diffuse HI
who fail medical management will require a subtotal
pancreatectomy and placement of a gastrostomy tube to
help with the post-operative management since most of




Figure 3 A. Frontal view of a 3D maximum intensity projection (MIP) 18-fluoro L-3,4-dihydroxyphenylalanine positron emission
tomography (18 F-DOPA PET) image demonstrating a focal lesion in the tail of the pancreas (arrow). B. A frontal view 3D MIP 18 F-DOPA
PET image fused with a contrast-enhanced CT shows a focal lesion in the pancreatic head (white arrow). C. Frontal view of a 3D MIP showing
non-uniform pattern of uptake with increased activity throughout the pancreas consistent with diffuse disease. Note the normal liver, kidney and
bladder uptake.
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Hospital of Philadelphia, 95% of patients with focal
disease have been cured and the majority required
less than a 50% pancreatectomy. In contrast, the ma-
jority of patients with diffuse disease post-operatively
required continued intervention to maintain euglyce-
mia. However, after surgery, their HI can be more
easily medically managed. For children with continued
hypoglycemia, octreotide during the day combined
with continuous intragastric dextrose overnight is ef-
fective at preventing octreotide tachyphylaxis and
allows for stable glucose control. For the smaller subset
of patients with hyperglycemia following subtotal pancrea-
tectomy, insulin may be necessary. The long-term risk of
developing diabetes in children with diffuse disease
depends on the extent of pancreatic resection [52]. In thelargest published series, 91% of children who had under-
gone a near-total pancreatectomy in infancy required in-
sulin therapy for diabetes by the age of 14 years [53].
Conclusions
Congenital hyperinsulinism is one of the most compli-
cated and challenging disorders faced by pediatric endocri-
nologists. The potential for preventing permanent brain
damage caused by persistent hypoglycemia, makes it ex-
tremely important to identify and treat these children
early. The past two decades has seen tremendous progress
in understanding the genetic and molecular basis of HI.
This understanding has in turn lead to advancements
in management and improved outcomes, particularly
through the use of 18 F-DOPA PET scan to identify and
cure focal lesions.
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